AroCell Q1’22: Encouraging sales development and good cost control - Redeye

Redeye embraces AroCell’s Q1’22 report, demonstrating good cost control and higher sales than expected (albeit still in small figures). We slightly up our Base Case following the report - our fair value range suggests a hefty upside from today’s share price levels, but we emphasize the market volatility and an overhang from guarantors’ commitments from the rights issue.

Länk till analysen i sin helhet: https://www.redeye.se/research/840271/arocell-q122-encouraging-sales-development-and-good-cost-control?utm_source=finwire&utm_medium=RSS